Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Analysts following Egetis

 

Bryan, Garnier & Co: Oscar Haffen Lamm

Rx Securities: Joseph Hedden

Carnegie: Arvid Necander

Pareto Securities: Chien-Hsun Lee

ABG Sundal Collier: Alexander Krämer

Redeye: Fredrik Thor

 

 

 

 

 

Calendar and upcoming reports

August 22, 2024
Interim Report Q2 2024 (7:00am CEST)

November 8, 2024
Interim Report Q3 2024 (7:00am CET)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com